RU2370537C2 - Способ усиления иммунного ответа млекопитающего на антиген - Google Patents
Способ усиления иммунного ответа млекопитающего на антиген Download PDFInfo
- Publication number
- RU2370537C2 RU2370537C2 RU2006106848/13A RU2006106848A RU2370537C2 RU 2370537 C2 RU2370537 C2 RU 2370537C2 RU 2006106848/13 A RU2006106848/13 A RU 2006106848/13A RU 2006106848 A RU2006106848 A RU 2006106848A RU 2370537 C2 RU2370537 C2 RU 2370537C2
- Authority
- RU
- Russia
- Prior art keywords
- protein
- muc
- derivative
- nucleotide sequence
- immune response
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Изобретение относится к области биотехнологии, конкретно к вакцинации с использованием нуклеиновых кислот, и может быть использовано в медицине. Млекопитающему вводят местно имиквимод или резиквимод через 12-26 часов после введения нуклеотидных последовательностей, кодирующих гранулоцитарно-макрофагальный колониестимулирующий фактор и антигенный пептид или белок. Изобретение позволяет значительно усилить иммунный ответ млекопитающего на антиген. 17 з.п. ф-лы, 23 ил., 1 табл.
Description
Claims (18)
1. Способ усиления иммунного ответа млекопитающего на антиген, включающий введение следующих компонентов:
(1) агонист TLR-7, выбранный из имиквимода или резиквимода;
(2) нуклеотидная последовательность, кодирующая гранулоцитарно-макрофагальный колониестимулирующий фактор; и
(3) нуклеотидная последовательность, кодирующая антигенный пептид или белок,
при котором компонент (1) вводят местно через 12-26 ч после компонентов (2) и (3).
(1) агонист TLR-7, выбранный из имиквимода или резиквимода;
(2) нуклеотидная последовательность, кодирующая гранулоцитарно-макрофагальный колониестимулирующий фактор; и
(3) нуклеотидная последовательность, кодирующая антигенный пептид или белок,
при котором компонент (1) вводят местно через 12-26 ч после компонентов (2) и (3).
2. Способ по п.1, где одна или более чем одна нуклеотидная последовательность представляет собой последовательность ДНК.
3. Способ по п.1, где нуклеотидная последовательность закодирована в ДНК-плазмиде.
4. Способ по п.1, где нуклеотидная последовательность (3) кодирует белок P501S или его производное, которое способно усиливать иммунный ответ in vivo, причем этот иммунный ответ способен распознавать опухолевую клетку или опухоль, экспрессирующую P501S.
5. Способ по п.1, где нуклеотидная последовательность (3) кодирует белок MUC-1 (муцин-1) или его производное, которое способно усиливать иммунный ответ in vivo, причем этот иммунный ответ способен распознавать опухолевую клетку или опухоль, экспрессирующую MUC-1.
6. Способ по п.5, где белок MUC-1 или его производное не содержит каких-либо повторяющихся элементов (совершенных или несовершенных).
7. Способ по п.5, где белок MUC-1 или его производное не содержит каких-либо совершенных повторяющихся элементов.
8. Способ по п.5, где белок MUC-1 или его производное содержит от 1 до 15 повторяющихся элементов.
9. Способ по п.5, где белок MUC-1 или его производное содержит 7 совершенных повторяющихся элементов.
10. Способ по п.5, где нуклеотидная последовательность, кодирующая белок MUC-1 или его производное, имеет модифицированные кодоны.
11. Способ по п.5, где нуклеотидная последовательность, кодирующая участок с несовершенным повтором, имеет значение относительного использования синонимических кодонов по меньшей мере 0,6.
12. Способ по п.5, где нуклеотидная последовательность, кодирующая несовершенные повторяющиеся элементы белка MUC-1 или его производного, имеет уровень идентичности с MUC-1 ДНК дикого типа по соответствующим неповторяющимся участкам менее 85%.
13. Способ по п.5, где белок MUC-1 или его производное содержит измененный повтор (элементы VNTR (вариабельного числа тандемных повторов)), например мутанты с уменьшенным гликозилированием.
14. Способ по п.5, где белок MUC-1 или его производное представляет собой слитый белок или конъюгирован с чужеродными Т-клеточными эпитопами.
15. Способ по п.14, где белок MUC-1 или его производное представляет собой слитый белок или конъюгирован с Р2, или РЗО, или их фрагментами.
16. Способ по п.14, где чужеродные Т-клеточные эпитопы введены в молекулу или на любой конец белка MUC-1 или его производного.
17. Способ по любому из пп.1-16, где по меньшей мере один носитель компонента (2) или (3) представляет собой золотую гранулу и пригоден для доставки лекарственного средства посредством частиц.
18. Способ по п.17, где носитель для компонентов (2) и (3) представляет собой золотую гранулу, а компонент (1) приготовлен для последовательного введения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0321615.7 | 2003-09-15 | ||
GBGB0321615.7A GB0321615D0 (en) | 2003-09-15 | 2003-09-15 | Improvements in vaccination |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2006106848A RU2006106848A (ru) | 2007-10-27 |
RU2370537C2 true RU2370537C2 (ru) | 2009-10-20 |
Family
ID=29227139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006106848/13A RU2370537C2 (ru) | 2003-09-15 | 2004-09-13 | Способ усиления иммунного ответа млекопитающего на антиген |
Country Status (19)
Country | Link |
---|---|
US (1) | US20080145375A1 (ru) |
EP (1) | EP1682175A2 (ru) |
JP (1) | JP2007505827A (ru) |
KR (1) | KR20070029111A (ru) |
CN (1) | CN1878567A (ru) |
AU (1) | AU2004271726A1 (ru) |
BR (1) | BRPI0414381A (ru) |
CA (1) | CA2538197A1 (ru) |
GB (1) | GB0321615D0 (ru) |
IL (1) | IL174131A0 (ru) |
IS (1) | IS8363A (ru) |
MA (1) | MA28323A1 (ru) |
MX (1) | MXPA06002969A (ru) |
NO (1) | NO20061242L (ru) |
NZ (1) | NZ545948A (ru) |
RU (1) | RU2370537C2 (ru) |
SG (1) | SG145767A1 (ru) |
WO (1) | WO2005025614A2 (ru) |
ZA (1) | ZA200602156B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2642300C2 (ru) * | 2011-08-17 | 2018-01-24 | Глоубиммьюн, Инк. | Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
BRPI0412902A (pt) | 2003-08-12 | 2006-09-26 | 3M Innovative Properties Co | compostos contendo imidazo substituìdo por oxima |
CA2536136C (en) | 2003-08-27 | 2012-10-30 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
AU2004270201A1 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for CD5+ B cell lymphoma |
CA2540541C (en) | 2003-10-03 | 2012-03-27 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
US8598192B2 (en) | 2003-11-14 | 2013-12-03 | 3M Innovative Properties Company | Hydroxylamine substituted imidazoquinolines |
WO2005048933A2 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Oxime substituted imidazo ring compounds |
AU2004293078B2 (en) | 2003-11-25 | 2012-01-19 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
FR2863890B1 (fr) * | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
EP1701955A1 (en) | 2003-12-29 | 2006-09-20 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
WO2005066169A2 (en) | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides |
EP1699398A4 (en) * | 2003-12-30 | 2007-10-17 | 3M Innovative Properties Co | IMPROVING THE IMMUNE RESPONSE |
CA2559863A1 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
US20080248068A1 (en) | 2004-05-07 | 2008-10-09 | Hans-Gustaf Ljunggren | Use of Flagellin as an Adjuvant for Vaccine |
WO2005123080A2 (en) | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
US7915281B2 (en) | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
US8026366B2 (en) | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
WO2006038923A2 (en) | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
US7943609B2 (en) | 2004-12-30 | 2011-05-17 | 3M Innovative Proprerties Company | Chiral fused [1,2]imidazo[4,5-C] ring compounds |
ES2392648T3 (es) | 2004-12-30 | 2012-12-12 | 3M Innovative Properties Company | Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
EP1846405A2 (en) | 2005-02-11 | 2007-10-24 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods |
AU2006232377A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
CA2602590A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
WO2007011777A2 (en) | 2005-07-18 | 2007-01-25 | Novartis Ag | Small animal model for hcv replication |
CA2623764A1 (en) * | 2005-09-27 | 2007-04-05 | Coley Pharmaceutical Gmbh | Modulation of tlr-mediated immune responses using adaptor oligonucleotides |
ES2370040T3 (es) | 2005-10-07 | 2011-12-12 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. | Vacuna de metaloproteinasa 11 de la matriz. |
CA2523032A1 (en) | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
PL2347775T3 (pl) | 2005-12-13 | 2020-11-16 | President And Fellows Of Harvard College | Rusztowania do przeszczepiania komórek |
KR101273836B1 (ko) | 2006-02-28 | 2013-06-11 | 박사르트, 인크. | 키메라 아데노바이러스 벡터 |
WO2007109813A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
CA2652599C (en) | 2006-05-03 | 2019-09-24 | Ross Kedl | Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity |
JP5427027B2 (ja) * | 2006-05-03 | 2014-02-26 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド,ア・ボディー・コーポレイト | Cd40アゴニスト抗体/i型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用 |
WO2008008432A2 (en) | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
NZ574239A (en) | 2006-07-18 | 2011-12-22 | Glaxosmithkline Biolog Sa | Hybrid fusion proteins for malaria vaccines |
GB0617387D0 (en) * | 2006-09-04 | 2006-10-11 | Glaxo Group Ltd | Synthetic gene |
SI2137210T1 (sl) | 2007-03-02 | 2017-01-31 | Glaxosmithkline Biologicals S.A. | Nov postopek in sestavki |
DE102007044093A1 (de) * | 2007-09-14 | 2009-03-19 | Phenion Gmbh & Co. Kg | Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Induktion antimikrobieller Peptide in epithelialen Deckgeweben |
CN101827613A (zh) | 2007-09-27 | 2010-09-08 | 免疫疫苗技术有限公司 | 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用 |
US9138470B2 (en) * | 2007-11-02 | 2015-09-22 | The Johns Hopkins University | Multi-component L2 vaccine for prevention of human papilloma virus infection |
KR100900837B1 (ko) * | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물 |
WO2009102465A2 (en) | 2008-02-13 | 2009-08-20 | President And Fellows Of Harvard College | Continuous cell programming devices |
JP5190628B2 (ja) * | 2008-03-31 | 2013-04-24 | 一般財団法人阪大微生物病研究会 | 混合免疫賦活剤を含む新規ワクチン |
US8425919B2 (en) | 2008-05-21 | 2013-04-23 | Infectious Disease Research Institute | Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis |
US8410258B2 (en) | 2008-05-21 | 2013-04-02 | Infections Disease Research Institute | Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis |
CA2723918C (en) | 2008-06-05 | 2018-01-09 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
US20100160368A1 (en) | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
EP2331119A4 (en) * | 2008-09-24 | 2012-05-30 | Univ Johns Hopkins | MALARIA VACCINE |
CN102325790A (zh) * | 2008-12-03 | 2012-01-18 | 西马生物医学计划公司 | 应用酚可溶性调控蛋白研制疫苗 |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
PL2376107T3 (pl) | 2008-12-09 | 2014-09-30 | Coley Pharm Group Inc | Oligonukleotydy immunostymulujące |
WO2010135747A1 (en) | 2009-05-22 | 2010-11-25 | Genocea Biosciences Inc. | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
CA2767392C (en) | 2009-07-06 | 2017-03-14 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
US9907746B2 (en) | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
MX336923B (es) | 2009-07-13 | 2016-02-05 | Medicis Pharmaceutical Corp | Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perianales. |
US20110077263A1 (en) * | 2009-09-29 | 2011-03-31 | University Of Southern California | Methods and Compositions of Toll-Like Receptor (TLR) Agonists |
CA2798074A1 (en) * | 2010-04-27 | 2011-11-03 | The Johns Hopkins University | Immunogenic compositions and methods for treating neoplasia |
CA2840079C (en) | 2010-07-06 | 2018-07-03 | Variation Biotechnologies Inc. | Compositions and methods for treating influenza |
LT2606047T (lt) * | 2010-08-17 | 2017-04-10 | 3M Innovative Properties Company | Imuninio atsako modifikatoriaus junginio lipidizuotos kompozicijos, sudėtys ir būdai |
US8932575B2 (en) * | 2010-09-21 | 2015-01-13 | University Of Miami | Compositions and methods for inducing migration by dendritic cells and an immune response |
JP6104806B2 (ja) | 2010-10-06 | 2017-03-29 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル |
EP2643014A4 (en) | 2010-11-24 | 2015-11-11 | Genocea Biosciences Inc | HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE |
FR2969657B1 (fr) | 2010-12-22 | 2014-02-07 | Fabre Pierre Dermo Cosmetique | Nouvelle bacterie et extraits de ladite bacterie et leur utilisation en dermatologie |
FR2969658B1 (fr) | 2010-12-22 | 2014-10-17 | Fabre Pierre Dermo Cosmetique | Nouvelle bacterie et extraits de ladite bacterie et leur utilisation therapeutique |
WO2012097346A1 (en) | 2011-01-13 | 2012-07-19 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
US9308253B2 (en) | 2011-09-19 | 2016-04-12 | The Johns Hopkins University | Cancer immunotherapy |
EP2763698B1 (en) | 2011-10-06 | 2020-12-02 | ImmunoVaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof |
CA2885693C (en) | 2011-11-23 | 2020-07-28 | Genocea Biosciences, Inc. | Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
EP2802353A4 (en) | 2012-01-12 | 2015-12-02 | Variation Biotechnologies Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS |
US20150079077A1 (en) | 2012-01-27 | 2015-03-19 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
LT2838515T (lt) | 2012-04-16 | 2020-03-10 | President And Fellows Of Harvard College | Mezoporinės silico dioksido kompozicijos, skirtos imuninio atsako moduliavimui |
KR101501583B1 (ko) * | 2013-03-29 | 2015-03-12 | 주식회사 차백신연구소 | 리포펩티드 및 폴리(i:c)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물 |
WO2014163213A1 (en) * | 2013-04-05 | 2014-10-09 | Kyushu University, National University Corporation | Anti-tumor dna vaccine |
SG11201510746WA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Respiratory syncytial virus (rsv) vaccine |
EP3524262A1 (en) * | 2013-11-01 | 2019-08-14 | Pfizer Inc | Vectors for expression of prostate-associated antigens |
WO2015092710A1 (en) | 2013-12-19 | 2015-06-25 | Glaxosmithkline Biologicals, S.A. | Contralateral co-administration of vaccines |
JP7348708B2 (ja) | 2014-04-30 | 2023-09-21 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 組み合わせワクチン装置および癌細胞を殺滅する方法 |
US11786457B2 (en) | 2015-01-30 | 2023-10-17 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
EP3280464A4 (en) | 2015-04-10 | 2018-09-26 | President and Fellows of Harvard College | Immune cell trapping devices and methods for making and using the same |
WO2016199904A1 (ja) * | 2015-06-10 | 2016-12-15 | 国立大学法人東京大学 | ワクチン用アジュバント、ワクチン、及び免疫誘導方法 |
CN105031646A (zh) * | 2015-07-16 | 2015-11-11 | 一达国际生物科技(北京)有限公司 | 抗肿瘤疫苗佐剂、其制备方法和编码核酸以及抗肿瘤疫苗组合物 |
WO2017024084A1 (en) | 2015-08-03 | 2017-02-09 | University Of Washington | Immunogenic compositions, antigen screening methods, and methods of generating immune responses |
CN109072197A (zh) | 2016-02-06 | 2018-12-21 | 哈佛学院校长同事会 | 重塑造血巢以重建免疫 |
WO2018013797A1 (en) | 2016-07-13 | 2018-01-18 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
WO2018064232A1 (en) | 2016-09-28 | 2018-04-05 | Genocea Biosciences, Inc. | Methods and compositions for treating herpes |
WO2021231971A1 (en) * | 2020-05-14 | 2021-11-18 | Ascendo Biotechnology, Inc. | Selective targeting of the treml1/md2 interaction by small peptide or protein and its use for vaccine adjuvants |
CN114377122B (zh) * | 2022-01-18 | 2023-04-07 | 四川大学 | 一种基于四面体框架核酸的复合佐剂、mRNA疫苗及其制备方法和用途 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5697901A (en) | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
CA2085827C (en) | 1991-12-23 | 2003-10-14 | Lucas A. T. Hilgers | Adjuvant composition containing synthetic hydrophobic lipopolysaccharide |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
EP0812593B8 (en) | 1993-03-23 | 2010-11-10 | SmithKline Beecham Biologicals S.A. | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
WO1995014026A1 (en) | 1993-11-17 | 1995-05-26 | Laboratoires Om S.A. | Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use |
CA2501743C (en) | 1994-01-21 | 2008-11-18 | Powderject Vaccines, Inc. | Gas driven gene delivery instrument |
DE69836206T2 (de) | 1997-02-07 | 2007-08-23 | Merck & Co., Inc. | Synthetische hiv gag gene |
EP0971739B1 (en) | 1997-04-01 | 2004-10-06 | Corixa Corporation | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
US6130043A (en) * | 1997-05-02 | 2000-10-10 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
DE69929310T2 (de) | 1998-02-05 | 2006-08-03 | Glaxosmithkline Biologicals S.A. | Tumorassoziierte antigenderivate der mage-familie, nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung |
CN1629185B (zh) | 1998-04-07 | 2011-11-02 | 科里克萨公司 | 结核杆菌抗原融合蛋白及其应用 |
DE60044665D1 (de) | 1999-01-29 | 2010-08-26 | Corixa Corp | Her2/neu fusionsproteine |
GB9930359D0 (en) * | 1999-12-22 | 2000-02-09 | Glaxo Group Ltd | Novel polypeptides |
GB0027088D0 (en) | 2000-11-06 | 2000-12-20 | Glaxo Group Ltd | DNA expression vectors |
BR0112637A (pt) | 2000-07-21 | 2003-06-10 | Glaxo Group Ltd | Sequências do vìrus do papiloma códon-otimizadas |
EP1478371A4 (en) * | 2001-10-12 | 2007-11-07 | Univ Iowa Res Found | METHODS AND PRODUCTS FOR ENHANCING IMMUNE RESPONSES USING IMIDAZOQUINOLINE COMPOUND |
GB0212046D0 (en) | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
CN100360558C (zh) | 2002-06-11 | 2008-01-09 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
-
2003
- 2003-09-15 GB GBGB0321615.7A patent/GB0321615D0/en not_active Ceased
-
2004
- 2004-09-13 WO PCT/EP2004/010322 patent/WO2005025614A2/en active Application Filing
- 2004-09-13 JP JP2006525795A patent/JP2007505827A/ja active Pending
- 2004-09-13 MX MXPA06002969A patent/MXPA06002969A/es not_active Application Discontinuation
- 2004-09-13 EP EP04765233A patent/EP1682175A2/en not_active Withdrawn
- 2004-09-13 CN CNA2004800329600A patent/CN1878567A/zh active Pending
- 2004-09-13 SG SG200806232-5A patent/SG145767A1/en unknown
- 2004-09-13 RU RU2006106848/13A patent/RU2370537C2/ru not_active IP Right Cessation
- 2004-09-13 KR KR1020067007205A patent/KR20070029111A/ko not_active Application Discontinuation
- 2004-09-13 US US10/571,812 patent/US20080145375A1/en not_active Abandoned
- 2004-09-13 AU AU2004271726A patent/AU2004271726A1/en not_active Abandoned
- 2004-09-13 CA CA002538197A patent/CA2538197A1/en not_active Abandoned
- 2004-09-13 NZ NZ545948A patent/NZ545948A/en unknown
- 2004-09-13 BR BRPI0414381-7A patent/BRPI0414381A/pt not_active IP Right Cessation
-
2006
- 2006-03-06 IL IL174131A patent/IL174131A0/en unknown
- 2006-03-14 ZA ZA200602156A patent/ZA200602156B/en unknown
- 2006-03-17 NO NO20061242A patent/NO20061242L/no not_active Application Discontinuation
- 2006-03-20 IS IS8363A patent/IS8363A/is unknown
- 2006-03-27 MA MA28896A patent/MA28323A1/fr unknown
Non-Patent Citations (2)
Title |
---|
BAEK K.M. et al., Comparative analysis of effects ofcytokine gene adjuvants on DNA vaccination against Mycobacterium tuberculosis heat shock protein 65, Vaccine, 2003, v.21, n.25-26, p.3684-3689. JURK M. et al., Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848, Nat. Immunol., 2002, v.3, n.6, p.499. HEMMI H. et al., Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway, Nat. Immunol., 2002, v.3, n.2, p.196-200. * |
SCHEERLINCK J.Y., Genetic adjuvants for DNA vaccines, Vaccine, 2001, v.19, n.17-19, p.2647-2656. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2642300C2 (ru) * | 2011-08-17 | 2018-01-24 | Глоубиммьюн, Инк. | Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения |
US10188714B2 (en) | 2011-08-17 | 2019-01-29 | Globeimmune, Inc. | Yeast-MUC1 immunotherapeutic compositions and uses thereof |
US11065318B2 (en) | 2011-08-17 | 2021-07-20 | Globeimmune, Inc. | Yeast-MUC1 immunotherapeutic compositions and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
MXPA06002969A (es) | 2007-03-26 |
SG145767A1 (en) | 2008-09-29 |
RU2006106848A (ru) | 2007-10-27 |
MA28323A1 (fr) | 2006-12-01 |
WO2005025614A3 (en) | 2005-10-06 |
IL174131A0 (en) | 2006-08-01 |
NZ545948A (en) | 2009-07-31 |
BRPI0414381A (pt) | 2006-11-21 |
JP2007505827A (ja) | 2007-03-15 |
GB0321615D0 (en) | 2003-10-15 |
CA2538197A1 (en) | 2005-03-24 |
AU2004271726A1 (en) | 2005-03-24 |
IS8363A (is) | 2006-03-20 |
CN1878567A (zh) | 2006-12-13 |
ZA200602156B (en) | 2007-07-25 |
WO2005025614A2 (en) | 2005-03-24 |
NO20061242L (no) | 2006-06-01 |
EP1682175A2 (en) | 2006-07-26 |
KR20070029111A (ko) | 2007-03-13 |
US20080145375A1 (en) | 2008-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2370537C2 (ru) | Способ усиления иммунного ответа млекопитающего на антиген | |
RU2263118C2 (ru) | Комплексы антител с несколькими цитокинами | |
JP4157277B2 (ja) | 実質的に純粋なヒスチジン結合タンパク質−ポリマー結合体 | |
CN102378635A (zh) | 重组人白蛋白-人粒细胞集落刺激因子融合蛋白的新稳定制剂 | |
Saenz‐Badillos et al. | RNA as a tumor vaccine: a review of the literature | |
EP1440090A2 (en) | A synthetic chimeric fusion protein with immuno-therapeutic uses | |
RU2002104700A (ru) | Слитые белки с Fc-фрагментом иммуноглобулина для повышения иммуногенности белковых и пептидных антигенов | |
JP2014012742A (ja) | 組換えエリスロポエチンと部分的に組合されたil−1インヒビターおよびtnfアンタゴニストの貧血治療用途 | |
JP2005520853A (ja) | 蛋白質ワクチン接種の有効なアジュバントとしての抗体融合蛋白質 | |
JP6466327B2 (ja) | 免疫調節ワクチン | |
RU2005119305A (ru) | Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2 | |
Bracci et al. | Type I interferons as vaccine adjuvants against infectious diseases and cancer | |
Lampreht Tratar et al. | Gene Electrotransfer of Plasmid‐Encoding IL‐12 Recruits the M1 Macrophages and Antigen‐Presenting Cells Inducing the Eradication of Aggressive B16F10 Murine Melanoma | |
US20210299186A1 (en) | Vaccination with mica/b alpha 3 domain for the treatment of cancer | |
AU2005220156B2 (en) | Peptides of IL1 beta and TNF alpha and method of treatment using same | |
EP2999485A1 (en) | Gastrin peptide immunogenic composition | |
US10022440B2 (en) | Materials and methods for modulating immune responses | |
Andrews et al. | Production and in vivo use of recombinant ovine IL-1β as an immunological adjuvant | |
EP1526185B1 (en) | Use of a microorganism or cell to induce autoimmunization of an organism against a tumor | |
WO2002077034A3 (en) | Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity | |
CN1143895C (zh) | 用基因工程方法生产增强其生物活性的红细胞生长因子二联体/三联体融合蛋白 | |
WO2024055272A1 (zh) | 能高效表达目的基因的mRNA载体系统、其构建及应用 | |
Fridman et al. | The use of cytokines in the treatment of solid tumours | |
CN115137814A (zh) | 一种肿瘤疫苗佐剂 | |
CN1806848A (zh) | 胸腺素α原基因的新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20100914 |